Microba Life Sciences Ltd (ASX:MAP) CEO Dr Luke Reid sits down with Proactive's Tylah Tully live from the ASX Small and Mid Cap Conference in September 2024.
Microba Life Sciences believes in comprehensive and precise measurement of the human gut microbiome to drive innovation in medical care.
Through its analysis and discovery platforms, the company identifies novel microbiome-derived therapeutics and new diagnostic tools to advance medicine.
The growing team is built on a foundation of scientific and technical excellence and a drive to discover ever-deeper insights into the relationships between gut microorganisms and health.
The company works with international partners who share its passion and scientific rigour to fast-track these new advances.